联合静态与动态[18F]FDG-PET及弥散加权MRI评估皮下患者来源子宫内膜癌小鼠模型的早期化疗反应
在两种来源于患者来源类器官的皮下子宫内膜癌小鼠模型中,联合卡铂与紫杉醇治疗组与生理盐水对照组相比,终点时T2w-MRI肿瘤体积、静态[18F]FDG-PET的SUV10及ADCmean均显示治疗反应;动态PET参数MRFDG在模型A第3天和终点显著降低,在模型B两组相似。多模态影像可用于评估临床前皮下子宫内膜癌模型的早期治疗反应,MRFDG动态PET参数似乎最有希望检测化疗后的极早期治疗反应。
要点
- 终点时两模型治疗组T2w-MRI肿瘤体积均低于对照组(p≤0.029)。
- 模型A治疗组MRFDG在第3天和终点显著降低(p≤0.042),模型B两组相似(p≥0.217)。
- 两模型终点治疗组SUV10显著较低(p≤0.041),ADCmean显著较高(p≤0.036)。
核心结论
- 多模态影像用于评估临床前皮下子宫内膜癌模型的早期治疗反应是可行的。
- 新型MRFDG动态PET成像参数似乎最有希望检测化疗后的极早期治疗反应。
研究设计与样本
- 研究将来源于患者来源类器官的子宫内膜样子宫内膜癌3级(EEC G3)、FIGO分期3C1(模型A)或1B(模型B)组织双侧注射至小鼠(n=15只小鼠)。
- 小鼠随机分为治疗组(卡铂联合紫杉醇,模型A 8个肿瘤/模型B 6个肿瘤)或对照组(生理盐水,模型A 8个肿瘤/模型B 8个肿瘤)。
- 在基线/第0天(治疗开始)、第3天(早期)和第10天(终点)使用序贯PET-MRI小动物扫描仪进行T2加权MRI、DW-MRI和动态[18F]FDG-PET。
主要发现
- 终点时T2w-MRI肿瘤体积(vMRI)在两个模型的治疗组均较低(p≤0.029)。
- 动态PET的肿瘤代谢率(MRFDG)在模型A治疗组第3天和终点显著较低(p≤0.042);模型B中MRFDG两组在第3天和终点相似(p≥0.217)。
- 静态[18F]FDG-PET中SUV最高的10个肿瘤体素(SUV10)在两个模型终点治疗组显著较低(p≤0.041),但在早期时间点无显著差异(p≥0.083)。
- 肿瘤平均表观弥散系数(ADCmean)在两个模型终点治疗组显著较高,提示治疗反应(p≤0.036)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of carboplatin and paclitaxel is the standard chemotherapy for treatment of high-risk and recurrent endometrial cancer. Evaluation of treatment response by diagnostic imaging is routinely carried out months after start of treatment, and is based on changes in tumor size or appearance of new metastases. The aim of this study was to evaluate early chemotherapeutic response in two subcutaneous endometrial cancer mouse models generated from patient-derived organoids using static- and dynamic [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) and diffusion-weighted (DW) magnetic resonance imaging (MRI). Mice were injected bilaterally with endometrioid endometrial cancer grade 3 (EEC G3), International Federation of Gynaecology and Obstetrics (FIGO) stage 3C1 (Model A) or stage 1B (Model B) organoids (n = 15 mice). The mice were randomized into treatment (combined carboplatin and paclitaxel, nA=8 / nB=6 tumors) or control (saline, nA=8 / nB=8 tumors) groups. During tumor progression, the mice underwent T2-weighted (T2w) MRI, DW-MRI and dynamic [18F]FDG-PET at baseline/Day 0 (start of treatment), Day 3 (early) and Day 10 (endpoint) using a sequential PET-MRI small-animal scanner. RESULTS: At endpoint, tumor volumes at T2w-MRI (vMRI) were lower in the treatment groups in both models (p ≤ 0.029). The tumor metabolic rate (MRFDG) from dynamic PET, was significantly lower in the treatment group at the early timepoint (Day 3) and at the endpoint in Model A (p ≤ 0.042). In Model B, MRFDG was similar for both groups at Day 3 and at endpoint (p≥0.217). The 10 tumor voxels with the highest standardised uptake value (SUV10) from static [18F]-FDG-PET was significantly lower at endpoint in the treatment groups in both models (p ≤ 0.041), but not at the early timepoint (p≥0.083). Similarly, the tumor apparent diffusion coefficient (ADCmean) was significantly higher indicating treatment response at endpoint for treatment groups in both models (p ≤ 0.036). CONCLUSIONS: Multimodal imaging is feasible for evaluation of early signs of treatment response in preclinical subcutaneous endometrial cancer models. The novel MRFDG dynamic PET imaging parameter seems most promising for detecting very early treatment response following chemotherapy.
引用
- Espedal H, Lyngstad JM, Berg HF, et al. Evaluation of early chemotherapy response by combining static- and dynamic [18F]FDG-PET with diffusion-weighted MRI in subcutaneous patient-derived endometrial cancer mouse models. EJNMMI Res. 2025. PMID: 40251389. doi:10.1186/s13550-025-01235-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。